Study Finds Lymphoma Accelerates Aging of Immune Cells and Tissues
A new study reveals lymphoma can accelerate the biological aging of the immune system and other tissues.
NIH Changes Terms and Conditions Governing Federal Grants
The National Institutes of Health announced a significant change to the terms and conditions governing federal funding applicable to all NIH grants, cooperative agreements and other awards, including future awards.
New Vaccine Shows Promise Against Pancreatic Cancer
Early clinical and preclinical results are showing that an experimental mRNA and nanoparticle vaccine produced measurable immune responses against pancreatic cancer, and that in small patient groups, those immune responses correlated with delayed recurrence or prolonged survival.
HHS Reinstates Childhood Vaccine Safety Task Force
The U.S. Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a long-dormant federal panel created by Congress to oversee the safety and quality of children’s vaccines.
FDA Requires Major Changes to Opioid Pain Medication Labeling
The U.S. Food and Drug Administration is requiring safety labeling changes to all opioid pain medications to better emphasize and explain the risks associated with their long-term use.
Argenx Is Conducting a Phase IV Study to Assess Efgartigimod Ph20 SC to Treat Adult CIDP Patients
Argenx is conducting a Phase IV clinical study to evaluate how adults with chronic inflammatory demyelinating polyneuropathy transition from intravenous immune globulin treatment to efgartigimod PH20 SC.
HHS Cuts Funding for mRNA Vaccine Research
The U.S. Department of Health and Human Services (HHS) has begun a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA).
FDA Fast Tracks Immunotherapy for HER2-Positive Breast Cancer Recurrence
The U.S. Food and Drug Administration has granted fast track designation for Greenwich LifeSciences’ lead immunotherapy candidate GLSI-100 in HLA-A*02–positive, HER2-positive breast cancer patients who have completed standard HER2-targeted therapy.
IVIG Reduces Infections Following BsAB Therapies in Multiple Myeloma Patients
A recent study showed treatment with intravenous immune globulin following infection from BCMA therapies yielded a 67 percent decrease in infections in patients with multiple myeloma.
FDA Approves Merck’s KEYTRUDA QLEX for Solid Tumor Indications
The U.S. Food and Drug Administration has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).